SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
89bio, Inc. (ETNB) , forward earnings yield 1.50%.
Criteria proven by this page:
- VALUE (90/100, Pass) — analyst target implies upside (+48.2%).
- Forward P/E 66.7
- Analyst consensus target $22.00 (+48.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
90/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ETNB
Valuation Multiples
P/E (TTM)0.0
Forward P/E66.7
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.51
Forward EPS (Est.)$0.22
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield1.50%
Dividend Yield0.00%
Analyst Target$22.00 (+48.2%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-3.53 |
$0.00 |
$-16.18M |
- |
| 2019 |
$-5.40 |
$0.00 |
$-57.42M |
- |
| 2020 |
$-3.08 |
$0.00 |
$-49.5M |
- |
| 2021 |
$-4.48 |
$0.00 |
$-90.12M |
- |
| 2022 |
$-2.93 |
$0.00 |
$-102.03M |
- |
| 2023 |
$-2.00 |
$0.00 |
$-142.19M |
- |
| 2024 |
$-3.51 |
$0.00 |
$-367.08M |
- |
